Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

20061,313 citationsJournal Article

Authors

Alan F. List · University of South Florida

Gordon W. Dewald · Mayo Clinic in Arizona

John M. Bennett · University of Rochester

Aristoteles Giagounidis · St.-Johannes-Hospital Dortmund

Azra Raza · University of Massachusetts Chan Medical School

Eric J. Feldman · Cornell University

Bayard L. Powell

Abstract

Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion. (ClinicalTrials.gov number, NCT00065156 [ClinicalTrials.gov].).

Topics & Keywords

Acute Myeloid Leukemia Research Chronic Lymphocytic Leukemia Research Chronic Myeloid Leukemia Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 355, Issue 14, pp. 1456-1465

DOI: 10.1056/nejmoa061292

Field-Weighted Citation Impact: 40.67